REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2018

Jan 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2018-01-02

Reporting Person: GOLDSTEIN JOSEPH L (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-02	Non-Qualified Stock Option (right to buy)	$380.95	A	7439	Acquired	2028-01-02	Common Stock (7439)	Direct

Footnotes

F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.